Spaulding Clinical Research announced the successful integration and electronic transfer of study data from Spaulding's clinical trial management system (CTMS) to the Medidata Rave electronic data capture (EDC) and clinical data management (CDM) system for a major global pharmaceutical client conducting a Phase I endocrinology indication.
Last June, Spaulding Clinical was recognized by Medidata Solutions as a Medidata Technology Partner after leveraging Medidata Web Services application programming interfaces (APIs) to enable data collected in Spaulding's Phase I unit, including clinical conduct, laboratory, vital signs and ECG data to be automatically transferred into Medidata Rave. Spaulding pioneered the full integration of Medidata Rave Phase I study data demonstrating the efficiency gained from using EDC in a clinical pharmacology environment. The integration enables the rapid transfer of all clinical pharmacology data, including ECG data, into Medidata Rave. Sponsors benefit from Rave data management capabilities for Phase I trials and the ability to more easily view clinical data from all trial phases in Rave.
"The use of the interface on this TQT study delivered flawless data, removed human error, and demonstrated significant cost and time savings," stated Brock Heinz, Vice President of Engineering for Spaulding Clinical.
Using the traditional industry model, manual transcription of the study from the Phase I EDC system delayed study completion by six weeks, increased cost by more than $25,000, and introduced hundreds of transcription errors. In the Spaulding Clinical model, electronic data transfer is completed error-free within minutes of approval to transfer, thus shaving weeks from study timelines.
All study data can be transferred in realtime, or at any defined interval during the normal flow of study conduct, providing sponsors with the latest information at all times.
Spaulding Clinical will be demonstrating their cutting-edge clinical pharmacology and data solutions as well as the new Spaulding iQSM Electrocardiograph and Core ECG Lab Solutions in booth 1905 at the DIA Annual Meeting taking place June 19 – 22, 2011, Chicago, IL.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.